Oral Cancer Rapid Test Kit Market Size, Share and Trends 2025 to 2034

Oral Cancer Rapid Test Kit Market Size and Forecast 2025 to 2034

The global oral cancer rapid test kit market size was accounted for USD 2.26 billion in 2024 and is expected to exceed around USD 3.76 billion by 2034, growing at a CAGR of 5.21% from 2025 to 2034. The increased public awareness for early detection of oral cancer is the key factor driving the growth of the global oral cancer rapid test kit market. The easy accessibility of kits in retail stores and online platforms is expanding the market growth.

Oral cancer rapid test kit market key takeaways

• North America dominated the global oral cancer rapid test kit market with the largest market share in 2024.
• Asia Pacific is projected to grow at a significant CAGR over the forecast period. 
• By product, the OncAlert oral cancer lab segment contributed the maximum market share in 2024.
• By principle, the immunoassay segment dominated the market in 2024.
• By end user, the hospitals segment and the diagnostic center segment has held a major market share in 2024.
• By end-user, the consumer segment is expected to witness notable growth in the market over the forecast period.

Future of Oral Cancer Rapid Test Kit Market with Artificial Intelligence (AI)

Artificial intelligence is the crucial technology that helps to provide accurate detection of oral cancers and their early symptoms. The integration of AI in the oral cancer rapid test kit market has improved the precision and accuracy of oral cancer detection. AI helps to detect cancer symptoms and roots within a minimum time, as it has become a time-saving technology tool. The home-based healthcare trend has become an initial and major adopter of the AI-based diagnostic solution to generate better outcomes.

The integration of AI in the oral cancer rapid test kit market represents the emerging steps for early, accurate detection and efficient management of oral cancer. The leverage of AI has made it possible for the development of noninvasive diagnostic solutions, which are encouraging the adoption of oral cancer rapid test kits as more convenient and user-friendly solutions. Technological advancements are allowing for more convenient, sensible, and selective oral cancer rapid test kits. Including saliva testing, the OncAlert Oral Cancer LAB test, immunoassay-based testing, sensor-based testing, and point-of-care testing solutions

• In October 2024, the U.S. Food and Drug Administration (FDA) gave technology approval as a "breakthrough device to Cancinstancet™, developed by Viome. The device is an AI-based, non-invasive one that looks for oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) and uses saliva to detect early symptoms of oral and throat cancer with more than 90% accuracy.

Market Overview

The prevalence of oral cancer has rapidly increased in recent years across the world due to several factors, including the use of smokeless tobacco, areca nut, and an aging population. Furthermore, the rise in the elderly population has contributed to the range of oral cancers. Elderly patients are continuously seeking convenient, user-friendly diagnostic solutions. The oral cancer rapid test kit market provides easy-to-handle, affordable, accessible, and quick yet accurate results. 

• According to Dr. Harriet Rumgay, a scientist in the Cancer Surveillance Branch at IARC, more than 120,000 people across the globe were diagnosed with oral cancer caused by smokeless tobacco or areca nut.

The government's focus and initiatives to promote awareness of oral cancer are enhancing public knowledge and addressing the need for early detection of cancer. Additionally, government funding in the oral cancer rapid test kit market and investments in advancing healthcare are making it easy to adopt cutting-edge solutions, including cancer rapid test kits. 

Rising collaboration between academic and research institutes is opening novel doors for the development of innovative technologies. Expanding healthcare infrastructure is providing accessibility to advanced and convenient diagnostic solutions. Additionally, the growing trend of home healthcare has increased the adoption of testing kits due to their easy accessibility in retail and online platforms and their easy handling and sensitive abilities. 

Oral Cancer Rapid Test Kit Market Growth factors

• Increasing prevalence of oral cancers: The prevalence of oral cancer has increased due to several factors, like tobacco and areca nut consumption. Additionally, the incidence is rapidly rising in the elderly population, making it essential for convenient and user-friendly diagnostic solutions, including in the oral cancer rapid test kit market.
• Growing awareness: the rising prevalence of oral cancers has emerged more awareness of cancer and the importance of early detections. Additionally, the increased adoption of oral cancer screening programs in dental clinics has driven the adoption of oral cancer rapid test kits.
• Government initiatives & funding: The growing government focus on oral cancer research, treatment innovation, and developments has led to funding in the sector. The several policies and campaigns for enhancing public awareness have been led by the government, leading to boosting the market expansion.
• Adoption of home healthcare: The trend toward home healthcare has risen since the COVID-19 pandemic. Patients are seeking flexible, convenient, and affordable diagnostic solutions. The easy accessibility of oral cancer testing kits has merged their adoption in home-based healthcare.
• Technology advancements: The technology advancements have improved the sensitivity & specificity nature of kits, making them more accurate and reliable. Additionally, developments of point-of-care testing and enhancing accuracy & speed of testing kits, making them more prior by healthcare professionals and patients.

Market Scope

Market dynamics

Drivers

Technology advancements

Advancements in technology are key drivers of the global oral cancer rapid test kit market. Technology advancements such as point-of-care testing systems, lab-on-chip technology, immunoassay-based tests, and biomarker-based testing are leveraging the novel approach of more accurate, reliable, quicker, and user-friendly oral cancer rapid test kits. Additionally, developments of non-invasive diagnostic kits are improving lab settings, which helps to reduce expenses and time consumption. Such technological developments are improving the accuracy and speed of rapid test kits, making them more preferred by healthcare professionals and patients. Technological advancements also allow patients to use self-use kitskits.

Restraint

Lack of awareness

The lack of awareness of oral cancer rapid test kits among healthcare professionals and patients is the major restraint of the oral cancer rapid test kit market. Despite the rising prevalence of oral cancer and its risk factors, there is insufficient acknowledgment of test kits among people. The limited priority of oral cancer compared to other types of cancers is the key hamper of this knowledge and awareness. The limited understanding of the importance of early detection and the lack of healthcare provider education hampers the adoption of test kits. Launching public awareness campaigns and education programs can help overcome such market challenges.

Opportunity

Home-based testing 

The rising prevalence of oral cancer has driven a surge in early diagnostic and convenient solutions. The rising trend toward home healthcare is holding the oral cancer rapid test kit market potential. Patients are seeking convenient, affordable, user-friendly, and accessible healthcare solutions. The kits are easy to handle and are cost-effective solutions for the detection of oral cancer. Additionally, the advancements in technologies are allowing for improved accuracy and user-friendly home-based testing solutions like oral cancer rapid test kits. 

Oral cancer is majorly witnessed in the aging population; the demand for home healthcare is high among elderly patients for their comfort and convenience. The easy availability of such kits on the internet is providing more access to cutting-edge technologies. With growing awareness and screening, the demand for oral cancer rapid test kits has increased in home-based diagnostic solutions, which further highlights potential essential advancements in the solution.

Product insights 

The OncAlert oral cancer lab segment led the oral cancer rapid test kit market in 2024. The segment growth is attributed to the non-invasive properties and user-friendly nature of the OncoAlert oral cancer test. OncAlert oral cancer lab tests provide an accurate understanding of the process of oral cancers and their possible diagnostics to physicians. Their reliability and accuracy have made them majorly preferred by healthcare professionals. Additionally, the proven effectiveness of OncAlert oral cancer lab tests in clinical settings is the key reason behind the segment expansion.

Principle insights

The immunoassay segment dominated the oral cancer rapid test kit market in 2024. The immunoassay tests are highly sensitive and specific in nature for detecting oral cancer biomarkers. The well-established immunoassay technology is widely used in clinical diagnostics. Additionally, the ability to detect a wide range of biomarkers is making them a priority to utilize for oral cancers. The segment growth is associated with the sensitive nature and rapid and precision result abilities of immunoassay-associated test kits.

End-user insights

The hospitals segment and the diagnostic center segment dominated the oral cancer rapid test kit market in 2024 due to the large number of patients in hospitals and diagnostic centers. The advancements of hospitals and diagnostic centers are making easy access to personalized oral cancer rapid test kits. Moreover, the availability of trained healthcare professionals to administer and interpret the outcomes of oral cancer rapid taste kits has been responsible for rising hospitalizations and patient enrollments in diagnostic centers. Government funding for cancer patients and easy access to advanced technologies in hospitals and diagnostic centers are the major factors driving segment growth.

On the other hand, the consumer segment is expected to witness notable growth in the oral cancer rapid test kit market over the forecast period as the demand for home healthcare and self-testing tools has increased. Companies are rapidly investing in innovations and developments of self-testing kits to provide quicker and more accurate results to comply with the rising prevalence of oral cancers. Additionally, the availability of oral cancer rapid test kits on online platforms and in retail stores.

Regional Insights

North America dominated the global oral cancer rapid test kit market in 2024 due to the rising prevalence of cancer and government initiatives and investments in key manufacturing companies. The well-established health infrastructure of North America is providing access to cutting-edge technologies, including oral cancer rapid test kits, for better outcomes for patients. The rising awareness and screening of oral cancer fueling the adoption rate of oral cancer rapid test kits. 

The United States is leading the North American oral cancer rapid test kit market due to a high oral cancer screening rate in the country. The rapidly growing elderly population has witnessed a large range of oral cancer. The heavy alcohol consumption and cigarette smoking incidence in the United States are also contributing to oral cancer. The advanced healthcare infrastructure and presence of key companies are making the possible success of oral cancer rapid test kits in the country. Canada is the second-largest country leading the regional market due to increased awareness of kits and screening rates.

• In February 2024, the National Institutes of Health (NIH) introduced a clinical trials network to develop novel technologies for cancer screening. The Cancer Screening Research Network (CSRN) is estimated to provide support to the Biden-Harris administration’s Cancer Moonshotâ„  by innovating the process of earlier cancer detection and accurate timing for treatment.

Asia Pacific will witness substantial growth in the oral cancer rapid test kit market over the forecast period. Asia has the largest patient pool with a prevalence of oral cancers due to a large number of smokeless tobacco consumers. Furthermore, the expanding healthcare expenditure and investments for the adoption of cutting-edge technologies in healthcare are allowing easy access to rapid test kits for the regional people. 

The rising awareness of oral cancers and screening rates is driving the adoption of the oral cancer rapid test kit market in Asia Pacific. Additionally, government funding for healthcare expenditure allows the utilization of such user-friendly, quick, and accurate technologies. Government investments and support from local manufacturers also contribute to market expansion. 

• According to a new study published in October 2024 by the International Agency for Research on Cancer (IARC) and its partner, which evaluates the global burden of oral cancer linked to smokeless tobacco and areca nut use, the study says that more than 120,000 cases of oral cancer occurred due to these risk factors in 2022. 

The Lancet Oncology analysis states that nearly 9 out of 10, that is, 88% of all oral cancer causes, are caused by smoking keless tobacco and areca nut in South-Central Asia. Countries like India, China, and Japan are leading the regional market due to the rising prevalence of oral cancer, rising awareness, and advancing healthcare expenditure.

• In 2022, in India, among women, the consumption rates of areca nut (30%), betel quid with tobacco (28%), gutka (21%), and khaini (21%) were responsible for oral cancer, and among men, khaini (47%), gutka (43%), betel quid with tobacco (33%), and areca nut (32%) were responsible for the oral cancer cases.

Oral cancer rapid test kit Market Competitors

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Quidel Corporation
• Danaher Corporation
• Abviris Deutschland GmbH
• Insilixa
• University of Sheffield
• Vigilant Biosciences
• Henry Schein, Inc
• Quest Diagnostics Incorporated
• F. Hoffmann-La Roche AG
• Becton
• Dickinson and Company

Latest Announcements by Industry Leaders

• In January 2024, Schwartz, professor of oral medicine and diagnostic sciences, announced the use of a brush biopsy diagnostic kit to analyze the impact of 600 different diseases that occur in the mouth and a number of these have already been characterized by microRNAs.
• In October 2023, Dr. Satish Wagh, Chairman of Supriya Lifescience Ltd., estimated the use of the QuickBlue oral kit to minimize the cost of oral cancer detection spectacularly and reduce the need for multiple biopsies in cases of non-healing oral ulcers.

Recent Developments

• In January 2024, Guy Adami and Dr. Joel Schwartz of the UIC College of Dentistry developed the brush biopsy, the diagnostic kit, which allows dentists to screen for the most common form of oral cancer.
• In August 2024, the Indian Institute of Technology Kanpur (IITK) transferred its Munh Parikshak, an oral cancer detection device, to Scangenie Scientific Pvt. Ltd., which is a portable, non-invasive and radiation-free way to screen for oral cancer.
• In October 2023, Supriya Lifescience Ltd., a well-known and specialist active pharmaceutical ingredient (API) manufacturing business, partnered with Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar, for the development of a novel oral cancer screening kit, ‘Quickblue oral kit.’ The kit is made to perform fast, cost-effectively, and accurately.

Segment Covered in the Report

By Product

• OncAlert Oral Cancer LAB
• Lab on Chip
• Insilixa Test
• Prevo-Check

By End-User

• Hospitals
• Diagnostic Centers
• Research Centers
• Consumer

By Principle

• Sensor-based
• Colorimetry
• Immunoassay
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa